Source link : https://newshealth.biz/health-news/selpercatinib-linked-to-long-term-survival-in-thyroid-cancer/
The first-in-class RET kinase inhibitor shows durable responses and favorable progression-free and overall survival rates in the 5-year final analysis of the LIBRETTO-001 trial. Medscape Medical News Source link : https://www.medscape.com/viewarticle/selpercatinib-linked-long-term-survival-thyroid-cancer-2025a1000pza?src=rss Author : Publish date : 2025-09-29 09:57:00 Copyright for syndicated content belongs to the linked Source.
The post Selpercatinib Linked to Long-Term Survival in Thyroid Cancer first appeared on News Health.
—-
Author : News Health
Publish date : 2025-09-29 09:57:00
Copyright for syndicated content belongs to the linked Source.
—-
1 – 2 – 3 – 4 – 5 – 6 – 7 – 8